Now showing items 1-4 of 4
Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease
(Journal article; Tidsskriftartikkel; Peer reviewed, 2018-11-10)
<i>Introduction</i>: The cerebrospinal fluid neurogranin (Ng)/β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) ratio may reflect synaptic affection resulting from reduced beta-amyloid (Aβ) clearance. We hypothesize that increased Ng/BACE1 ratio predicts the earliest cognitive decline in Alzheimer’s disease.<p> <p><i>Methods</i>: We compared Ng/BACE1 levels between cases with subjective ...
Screening for Alzheimer’s Disease: Cognitive Impairment in Self-Referred and Memory Clinic-Referred Patients
(Journal article; Tidsskriftartikkel; Peer reviewed, 2017-11-07)
<p>Background</i>: Cognitive assessment is essential in tracking disease progression in AD. Presently, cohorts including preclinical at-risk participants are recruited by different means, which may bias cognitive and clinical features. We compared recruitment strategies to levels of cognitive functioning.<p> <p><i>Objective</i>: We investigate recruitment source biases in self-referred and ...
Demographically adjusted CERAD wordlist test norms in a Norwegian sample from 40 to 80 years
(Journal article; Tidsskriftartikkel; Peer reviewed, 2019-03-08)
<i>Background/Objective</i>: In recent years, several slightly younger cohorts have been established in order to study the preclinical and prodromal phases of dementia. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) wordlist memory test (WLT) is widely used in dementia research. However, culturally adapted and demographically adjusted test norms for younger ages are ...
In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion
(Journal article; Tidsskriftartikkel; Peer reviewed, 2019-01-22)
<i>Background:</i> In the care of persons with cognitive problems, it is important to use a valid mild cognitive impairment (MCI) criterion that discriminates well between normal and pathological aging.<p> <p><i>Objective:</i> To find the brief neuropsychological screening criterion that best correlates with cerebrospinal fluid (CSF) biomarkers for cognitive decline and dementia in persons ...